Pharmacokinetic and pharmacodynamic properties of a new biosimilar filgrastim TPI G-CSF in comparison to the marketed reference filgrastim Neupogen®: a double-blind, single-dose, two-period crossover trial

Andrew Bourgoin, Sarfaraz Niazi
2015 Biosimilars  
doi:10.2147/bs.s86638 fatcat:puohwyo4ozayboxutjyg2pnyma